Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

The primary aim of the trial will be to determine, among psoriatic arthritis (PsA)patients with an inadequate response (IR) to a tumor necrosis factor inhibitor (TNFi),whether switching to a new mechanism of action (MOA), specifically guselkumab (GUS), aselective interleukin 23 inhibitor (IL23i) targeting the p19 subunit, is more effectivethan switching to another TNFi. The primary hypothesis of this study is that switching toa new MOA may be more effective than switching to a second TNFi. This will be the firsttrial to test such a switch in PsA patients. Additionally, the proposed study willaddress the effectiveness of a new therapy, GUS, in a clinical practice setting amongpatients who are TNF IR.